Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-09-25
2007-09-25
Saunders, David A. (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069700, C435S091200, C435S348000, C435S352000, C435S358000, C435S365000, C435S367000, C435S414000, C800S006000, C800S008000
Reexamination Certificate
active
11135155
ABSTRACT:
The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
REFERENCES:
patent: 4870009 (1989-09-01), Evans et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5132405 (1992-07-01), Huston et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 6248516 (2001-06-01), Winter et al.
patent: 6258360 (2001-07-01), von Borstel et al.
patent: 2062047 (1992-08-01), None
patent: 0302473 (1989-02-01), None
patent: 0361908 (1990-04-01), None
patent: 0382411 (1990-08-01), None
patent: 0392745 (1990-10-01), None
patent: 0404097 (1990-12-01), None
patent: 0501215 (1992-09-01), None
patent: WO88/07378 (1988-10-01), None
patent: WO88/09344 (1988-12-01), None
patent: WO89/10140 (1989-11-01), None
patent: WO91/00108 (1991-01-01), None
patent: WO91/08770 (1991-06-01), None
patent: WO91/11201 (1991-08-01), None
patent: WO93/13805 (1993-07-01), None
Furukawa et al, Current Opinion in Biotechnology, 3, 554-559, 1992.
B.D. Curti, Physical barriers to drug delivery in tumors , Crit. Rev. Oncol. Hematol, 1993, vol. 14, pp. 29-39.
Bosslet et al., Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation, British Journal of Cancer, 1992, pp. 234-238, vol. 65, No. 2.
Brinkman et al., Independent domain folding ofPseudomonas exotoxinand single-chain imunotoxins: Influence of interdomain connections, PNAS, 1992, pp. 3075-3079, vol. 89, No. 7.
Chatteerjee et al., Idiotypic antibody immunotherapy of cancer, Cancer Immunol. Immunother. Mar. 1994, vol. 38, No. 2, pp. 75-82.
Fremont et al., Biophysical Studies of T-Cell receptors and Their Ligands, Current Opin. Immunol., 1996, vol. 8, pp. 93-100.
Goochee et al., The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligsaccharide Structure And Their Effect on Glycoprotein, Biotechnology, 1991, pp. 1347-1355.
Gussow et al., Humanization of Monoclonal Antibodies, Methods in Enzymology, 1991, pp. 99-121, vol. 203.
Hellstrom et al., Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas, PNAS, 1986, pp. 7059-7063, vol. 83.
Hellstrom et al., Monoclonal Mouse Antibodies Raised Against Human Lung Carcinoma, Cancer Research, Aug. 1996, pp. 3917-3923, vol. 46, No. 8.
Hussain et al., Cloning and Sequencing of the Metallothioprotein-B-Lactamase II Gene ofBacillus cereus569/H inEscherichia coli, Journ of Bacteriology, 1985, pp. 223-229, vol. 164.
Huston et al., Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins, Methods in Enzymology, 1991, pp. 46-89, vol. 203.
Jain, Sci., America, 1994, pp. 58-63, vol. 271, No. 1.
Janeway et al., Immuno Biology, The Immune System in Health and Disease, Current Biology Limited, 1994, 12:33-12:36.
Jefferson et al., B-Glucuronidase fromEscherichia colias a gene-fusion marker, PNAS, 1986, pp. 8447-8451, vol. 83.
Kappel et al., Regulating gene expression in transgenic animals , Current Opinion: Biotechnology, 1992, pp. 548-553, vol. 3.
Kerr et al., Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoyxacetamide, Cancer Immuno. Immunother, 1990, pp. 202-206, vol. 31.
L.G. Presta, Antibody engineering, Current Opinion in Structural Biology, 1992, pp. 593-596, vol. 2.
Ong et al., Galactose-conjugated Antibodies in Cancer Therapy: Properties and Principles of Action, Cancer Research, Mar. 15, 1991, pp. 1619-1626, vol. 51.
Osband et al., Problems in the investigational study and clinical use of cancer immunotherapy , Immunology Today, 1990, pp. 193-195, vol. 11.
Presta et al., Humanization of an Antibody Directed Against IgE, Journ. of Immunology, Sep. 5, 1993, pp. 2623-2632, vol. 151, No. 5.
R.N. Perham, Domains, Motifs and Linkers in 2-Oxo Acid Dehydrogenase Multienzyme Complexis: A Paradigm in the Design of a Multifunctional Protein, Biochemistry, 1991, vol. 30, pp. 8501-8512.
Riechmann et al., Reshaping human antibodies for therapy, Nature, Mar. 1998, pp. 323-327, vol. 332.
Routledge et al., A humanized monovalent CD3 antibody which can activate homologous complement, Eur. J. Immunology, 1991, pp. 2717-2725, vol. 21.
Sharma et al., Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model, Brit. J. Cancer 1990, pp. 659-662, vol. 61.
Shearman et al., Construction, Expression and Characterization of Humanized Antibodies Directed Against The Human alpha/beta T Cell Receptor, J. of Immun. Dec. 15, 1991, pp. 4366-4373, vol. 147, No. 12.
Shields et al., Inhibition of Allergic Reactions with Antibodies to IgE, Int. Arch Allergy Immunology, 1995, pp. 308-312, vol. 107.
Sims et al., A Humanized CD18 Antibody Can Block Function without Cell Destruction, J. of Immun., Aug. 15, 1993, pp. 2296-2308, vol. 151, No. 4.
Suresh et al., Bispecific Monoclonal Antibodies from Hybrid Hybridomas, Methods in Enzymology, 1996, pp. 210-228, vol. 121.
Tempest et al., Reshaping A Human Monoclonal Antibody To Inhibit Human Respiratory Syncytial Virus Infection in Vivo, Biotechnology, Mar. 1991, pp. 266-271, vol. 9.
Tutt et al., Trispecific F(ab′)3 Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 To Activate and Redirect Resting Cytotoxic T Cells, J. of Immun., Jul. 1, 1991, pp. 60-69, vol. 147, No. 1.
Verhoeyen et al., Reshaping Human Antibodies: Grafting an Antilysozyme Activity, Science, Mar. 1988, pp. 1534-1536, vol. 239.
Waterhouse et al., Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires, Nucleic Acids Research 1993, pp. 2265-2266, vol. 121, No. 9.
Yang et al., CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody to the Picomolar Range, J. Mol Biol, 1995, pp. 392-403, vol. 254.
Andrianomenjanahary et al., N-(-D-Glycopyranosyl)-Chlorobenzyloxycarbonyl Daunorubicine Pro-Prodrugs and their enzymatic cleavage, Inst. Carbohydro. Symposium, Paris, 1992, p. 299, A264.
S. Brocklehurst, Re: Linker Peptide in Two-domain fusion protein, [http://www.bio.net/hypermail/protein-analysis/proteins. 199307/0048.html], Jul. 26, 1993.
Florent et al., N-(-D-Glycopyranosyl)-Benzyloxy-carbonyl Daunorubicine Pro-Prodrugs Synthesis and enzymatic behaviour, Inst. Carbohydr. Symp. Paris 1992, p. 297, A262.
Bosslet Klaus
Czech Jorg
Gehrmann Mathias
Seeman Gerhard
Behrinwerke Aktiengesellschaft
Saunders David A.
LandOfFree
Fusion proteins for prodrug activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fusion proteins for prodrug activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins for prodrug activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758834